Centocor
Executive Summary
Licenses worldwide exclusive rights to Corsevin M antithrombotic monoclonal antibody from Corvas, the company announced Nov. 18. Centocor will make a cash license payment and increase its equity in Corvas from 7% to 20%. Corvas also granted Centocor an exclusive option to license future monoclonal antibody products discovered and developed by the privately-held San Diego firm specializing in drug discovery and design of drugs for cardiovascular diseases. Phase I trials with Corsevin M began this summer. . . .